SALT LAKE CITY, April 24, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCBB:NUMD), a medical device development company, announced that on April 10, 2018, shareholders voted to re-elect all the existing highly qualified directors, Jeffrey Robins, William Moon, Thomas Tait, Dr. Craig Morrison and Dr. Brett J. Earl, to the Nu-Med Plus Board of Directors.
Sadler, Gibb and Associates LLC was also reaffirmed to serve as Nu-Med's independent registered public accounting firm and auditor.
Jeff Robins, Chairman of the Board and CEO of Nu-Med Plus, Inc., remarked, "I greatly appreciate the strong support from our shareholders and the reaffirmation of their confidence in the Board and our management team by re-electing all 5 of our incumbent directors. This strong vote of confidence recognizes their hard work and relentless focus since the inception of our company. We are more energized than ever about building on Nu-Med's strengths to anticipate and deliver our INO products to the medical community. We plan to maintain an active and productive dialogue with shareholders as we continue to transform our business and create value for all of our stakeholders."
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed Nitric Oxide technologies. The emphasis is to generate controlled-flow of INO for internal therapies with integrating accessories for availability in hospitals, emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries. For more company information please visit www.nu-medplus.com.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.